Bank of America Lowers Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $529.00

Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price objective cut by equities researchers at Bank of America from $570.00 to $529.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Bank of America‘s target price suggests a potential upside of 21.61% from the company’s previous close.

MDGL has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, January 22nd. Citigroup reiterated an “outperform” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday, January 20th. TD Cowen reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Monday, January 12th. Wolfe Research set a $579.00 price objective on Madrigal Pharmaceuticals in a research report on Tuesday, January 6th. Finally, Cantor Fitzgerald upgraded Madrigal Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $669.86.

Madrigal Pharmaceuticals Price Performance

MDGL opened at $435.01 on Friday. The company has a current ratio of 3.44, a quick ratio of 3.26 and a debt-to-equity ratio of 0.54. The company has a market cap of $9.88 billion, a price-to-earnings ratio of -33.80, a price-to-earnings-growth ratio of 6.18 and a beta of -1.01. The stock has a fifty day simple moving average of $521.61 and a two-hundred day simple moving average of $482.31. Madrigal Pharmaceuticals has a 12-month low of $265.00 and a 12-month high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). The business had revenue of $321.08 million during the quarter, compared to analysts’ expectations of $310.36 million. Madrigal Pharmaceuticals had a negative return on equity of 42.55% and a negative net margin of 30.08%.The firm’s quarterly revenue was up 210.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.71) earnings per share. Research analysts predict that Madrigal Pharmaceuticals will post -23.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Madrigal Pharmaceuticals

In related news, CEO William John Sibold sold 1,577 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $492.42, for a total transaction of $776,546.34. Following the sale, the chief executive officer directly owned 148,497 shares of the company’s stock, valued at $73,122,892.74. This trade represents a 1.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Rebecca Taub sold 647 shares of the company’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $492.42, for a total transaction of $318,595.74. Following the transaction, the director owned 452,704 shares in the company, valued at $222,920,503.68. This represents a 0.14% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 99,537 shares of company stock worth $53,485,702. Insiders own 21.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. increased its stake in shares of Madrigal Pharmaceuticals by 21.9% in the 4th quarter. Invesco Ltd. now owns 365,314 shares of the biopharmaceutical company’s stock worth $212,737,000 after purchasing an additional 65,749 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in Madrigal Pharmaceuticals during the fourth quarter valued at about $355,000. XTX Topco Ltd purchased a new stake in Madrigal Pharmaceuticals in the fourth quarter worth about $1,642,000. Wellington Management Group LLP increased its holdings in Madrigal Pharmaceuticals by 14.1% in the 4th quarter. Wellington Management Group LLP now owns 461,402 shares of the biopharmaceutical company’s stock worth $268,693,000 after acquiring an additional 56,947 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new stake in Madrigal Pharmaceuticals during the 4th quarter worth approximately $252,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra commercial strength: Q4 net sales of roughly $321.1M (Q4) and $958.4M for full‑year 2025, more than 36,250 patients on therapy and nearly $989M in cash and marketable securities — evidence of strong revenue growth and a sizeable cash runway. Press Release
• Neutral Sentiment: Investor materials and transparency: company provided an earnings slide deck and held a conference call — useful for modeling future margins, guidance and pipeline milestones. Earnings Presentation
• Negative Sentiment: Large EPS miss and rising expenses: reported Q4 EPS of ($2.57) vs. consensus ~$0.04, driven by a wider loss as expenses surged despite revenue beating estimates — this prompted an immediate negative market reaction. Zacks Article
• Negative Sentiment: Analyst action: Bank of America cut its price target (from $570 to $529) and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure. Benzinga

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.